NCT05880706View on ClinicalTrials.gov

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion

DRUG

Osimertinib Mesylate Tablets

Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY